XLON
VCT
Market cap1.07bUSD
Oct 09, Last price
942.00GBP
1D
1.95%
1Q
39.14%
Jan 2017
-51.22%
Name
Victrex PLC
Chart & performance
P/E
29.52
P/S
2.77
EPS
0.32
Div yield, %
6.41%
Shrs. gr., 5y
0.25%
Rev. gr., 5y
2.19%
Revenues
296m
+0.07%
Net income
28m
+61.63%
CFO
71m
-15.36%
Dividend
May 28, 202613.42 GBP/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Operating globally through its subsidiaries, Victrex plc is a specialized producer and distributor of polymer materials. The company organizes its business into two core divisions: Industrial and Medical. It concentrates on creating PEEK and PAEK polymer-based solutions, delivering both partially processed and fully manufactured components. Furthermore, Victrex offers tailored solutions for medical device producers, markets thermoplastic polymer components, and conducts trading operations. Its diverse clientele spans the automotive, aerospace, energy, industrial, manufacturing, engineering, electronics, and healthcare industries. Established in 1993, Victrex plc maintains its corporate headquarters in Thornton-Cleveleys, United Kingdom.
Related entities
Subsidiaries (2)
INVIBIO LIMITED
VICTREX MANUFACTURING LIMITED
Key people
Non-Executive Independent Chairman of the Board · since 2014
Martin L. Court
Managing Director - Invibio, Executive Director · since 2015
Chief Executive Officer, Executive Director · since 2017
Non-Executive Independent Director · since 2018
Non-Executive Independent Director · since 2018
Senior Non-Executive Independent Director · since 2020
Jane E. Toogood
Non-Executive Independent Director · since 2015
Headquarters & legal address
VICTREX TECHNOLOGY CENTRE
HILLHOUSE INTERNATIONAL
THORNTON CLEVELEYS, LAN FY5 4QD
GB
HILLHOUSE INTERNATIONAL
THORNTON CLEVELEYS, LAN FY5 4QD
GB
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑09 | 2024‑09 | 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | 2018‑09 | 2017‑09 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||